文献速递头颈部肿瘤放疗放疗物理与技术

每日智能辅助在线自适应放疗治疗头颈部肿瘤的真实世界临床经验

Real world clinical experience using daily intelligence-assisted online adaptive radiotherapy for head and neck cancer.
PubMed 文献 · Radiat Oncol · 2024-03-30

该研究评估了22例I–IVA期头颈部肿瘤患者接受基于每日CBCT的在线自适应放疗(ART)的初步临床经验,共生成770个自适应与计划放疗计划,其中703个(91.3%)自适应计划被选用。自适应计划较计划计划改善了PTV70、PTV59.5和PTV56的平均V95值,分别提高1.2%、7.2%和6.0%,PTV70平均最大剂量降低1.4%。中位随访14.1个月时,局部控制率为95.5%。

要点

  • 22例头颈部肿瘤患者接受每日在线自适应放疗,91.3%的自适应计划被选用。
  • 自适应计划较计划计划改善多个PTV的V95值,PTV70最大剂量平均降低1.4%。
  • 中位随访14.1个月局部控制率95.5%,9.1%患者出现急性3级吞咽困难。

核心结论

  • 这些发现提供了在头颈部肿瘤治疗中于CBCT上实施每日自适应放疗的可行性和剂量学获益的真实世界证据,需要前瞻性研究来确定这些剂量学改善是否转化为结局改善。

研究设计与样本

  • 研究评估了头颈部肿瘤患者使用具有智能辅助工作流程的在线自适应平台在每日CBCT上进行每日自适应放疗的初步临床经验,治疗包括危及器官和靶区结构的自动勾画与结构变形并由治疗医师调整,生成基于初始CT模拟勾画结构的计划计划与重新优化的自适应计划,两者评估后选用较优者执行并交付,回顾临床与剂量学结局。

主要发现

  • 22例头颈部肿瘤患者(鼻咽7例、口咽6例、口腔1例、喉8例)I–IVA期接受每日自适应放疗,共生成770个自适应和计划放疗计划,其中703个(91.3%)自适应计划被选用,实施自适应放疗的中位时间为20分钟(范围18–23)。
  • 自适应计划较计划计划显示PTV70、PTV59.5和PTV56的平均V95值分别提高1.2%、7.2%和6.0%,PTV70平均最大剂量降低1.4%。
  • 17个危及器官中有14个在自适应后显示剂量学改善,部分危及器官达到统计学显著。
  • 中位随访14.1个月时局部控制率为95.5%,2例患者发生转移性疾病,4例患者死亡。
  • 9.1%的患者出现急性3级吞咽困难,13.6%出现2级慢性口干症。

局限性

  • 原文指出需要前瞻性研究来确定这些剂量学改善是否转化为结局改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adaptive radiation therapy (ART) offers a dynamic approach to address structural and spatial changes that occur during radiotherapy (RT) for locally advanced head and neck cancers. The integration of daily ART with Cone-Beam CT (CBCT) imaging presents a solution to enhance the therapeutic ratio by addressing inter-fractional changes. METHODS: We evaluated the initial clinical experience of daily ART for patients with head and neck cancer using an online adaptive platform with intelligence-assisted workflows on daily CBCT. Treatment included auto-contour and structure deformation of Organs at Risk (OARs) and target structures, with adjustments by the treating physician. Two plans were generated: one based on the initial CT simulation with the edited structures (scheduled) and a re-optimized plan (adaptive). Both plans were evaluated and the superior one approved and delivered. Clinical and dosimetric outcomes were reviewed. RESULTS: Twenty two patients with head and neck cancers (7 Nasopharynx, 6 Oropharynx, 1 oral cavity, 8 larynx) stages I-IVA were treated with daily ART. 770 adaptive and scheduled radiotherapy plans were generated. 703 (91.3%) adaptive plans were chosen. Median time to deliver ART was 20 minutes (range: 18-23). Adaptive compared to scheduled plans demonstrated improved mean V95 values for the PTV70, PTV59.5, and PTV56 by 1.2%, 7.2%, and 6.0% respectively and a mean 1.4% lower maximum dose in PTV70. Fourteen of 17 OARs demonstrated improved dosimetry with adaptation, with select OARs reaching statistical significance. At a median follow up of 14.1 months, local control was 95.5%, two patients developed metastatic disease and four patients died. 9.1% of patients had acute grade 3 dysphagia and 13.6% had grade 2 chronic xerostomia. DISCUSSION: These findings provide real world evidence of the feasibility and dosimetric benefit of incorporating daily ART on CBCT in the treatment of head and neck cancer. Prospective study is needed to determine if these dosimetric improvements translate into improved outcomes.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Blumenfeld P, Arbit E, Den R, et al. Real world clinical experience using daily intelligence-assisted online adaptive radiotherapy for head and neck cancer. Radiat Oncol. 2024. PMID: 38555453. doi:10.1186/s13014-024-02436-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。